Safety and efficacy of artesunate treatment in severely injured patients with traumatic hemorrhage. The TOP-ART randomized clinical trial.

"Declarations Conflicts of interestThe authors declare they have no conflict of interest, including financial interests, activities, relationships, and affiliations in relation with the TOP-ART Trial. Ethical approvalThe trial was authorized by the Medicines and Healthcare products Regulation Authority (ref: 21313/0052/001-0001) on the 22nd January 2016 and approved by London City and East Research Ethics Committee (reference: 16/LO/003) on 11th March 2016. The trial was registered prospectively with the EU Clinical Trials Register (Identifier 2015-000301-40) and the ISRCTN (Identifier 15731357) on the 28th August 2015. Consent to participateThe trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or, in cases of impaired capacity, their closest relative or appropriate representative. Conflicts of interest The authors declare they have no conflict of interest, including financial interests, activities, relationships, and affiliations in relation with the TOP-ART Trial."

"Funding This research was funded by the Wellcome Trust (Grant Reference Number: 101012/Z/13/Z) and Department of Health (Grant Reference Number: HICFR7405)."

"Declarations: Conflicts of interestThe authors declare they have no conflict of interest, including financial interests, activities, relationships, and affiliations in relation with the TOP-ART Trial.: Ethical approvalThe trial was authorized by the Medicines and Healthcare products Regulation Authority (ref: 21313/0052/001-0001) on the 22nd January 2016 and approved by London City and East Research Ethics Committee (reference: 16/LO/003) on 11th March 2016. The trial was registered prospectively with the EU Clinical Trials Register (Identifier 2015-000301-40) and the ISRCTN (Identifier 15731357) on the 28th August 2015.: Consent to participateThe trial was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants or, in cases of impaired capacity, their closest relative or appropriate representative. Ethical approval: The trial was authorized by the Medicines and Healthcare products Regulation Authority (ref: 21313/0052/001-0001) on the 22nd January 2016 and approved by London City and East Research Ethics Committee (reference: 16/LO/003) on 11th March 2016. The trial was registered prospectively with the EU Clinical Trials Register (Identifier 2015-000301-40) and the ISRCTN (Identifier 15731357) on the 28th August 2015."